← Leaderboards
Zhaoyang You
University Of Pittsburgh At Pittsburgh
$2,731,696
Attributed
$2,731,696
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $422.3K · FY2006–25$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,731,696 · 4
By mechanism
R01$1,518,937 · 1
R21$1,212,759 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hassane M Zarour$16,372,397
- Dario Aa Vignali$40,087,127
- Lisa Helene Butterfield$10,558,896
- Robert J Binder$5,876,082
- Michael T Lotze$5,139,928
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteDendritic CellsTumor ImmunityImmunityMalignant NeoplasmsMediatingVaccine EfficacyVaccinationAdjuvantMelanomaTumorImmunizationVaccinesProteinsAntigensResponseImmunogenicRegulationTlr4 GenePlayCell SurvivalCd8b1 GeneIn VivoImmune Response
Grant awards (12)
A Novel Vaccine Adjuvant KOR-selective Small Molecule Agonist$190,490
R21 · FY2025 · AI · contact PI
A Novel Vaccine Adjuvant KOR-selective Small Molecule Agonist$230,240
R21 · FY2024 · AI · contact PI
In-Clinic Latanoprost As a Novel Vaccine Adjuvant$198,230
R21 · FY2022 · AI · contact PI
In-Clinic Latanoprost As a Novel Vaccine Adjuvant$234,750
R21 · FY2021 · AI · contact PI
Tumor Cell-derived HMGB1-initiated Activation of Treg$162,777
R21 · FY2016 · CA · contact PI
Tumor Cell-derived HMGB1-initiated Activation of Treg$196,272
R21 · FY2015 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$278,672
R01 · FY2010 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$278,672
R01 · FY2009 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$143,613
R01 · FY2009 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$278,672
R01 · FY2008 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$278,672
R01 · FY2007 · CA · contact PI
In Vivo Targeted Vaccines for Tumor Immunotherapy$260,636
R01 · FY2006 · CA · contact PI